Background: Low back pain (LBP) and neck pain (NP) are a major public health problem with considerable costs for individuals, companies and society. Therefore, prevention is imperative. The Stay@Work study investigates the (cost-)effectiveness of Participatory Ergonomics (PE) to prevent LBP and NP among workers.
Methods: In a randomised controlled trial (RCT), a total of 5,759 workers working at 36 departments of four companies is expected to participate in the study at baseline. The departments consisting of about 150 workers are pre-stratified and randomised. The control departments receive usual practice and the intervention departments receive PE. Within each intervention department a working group is formed including eight workers, a representative of the management, and an occupational health and safety coordinator. During a one day meeting, the working group follows the steps of PE in which the most important risk factors for LBP and NP, and the most adequate ergonomic measures are identified on the basis of group consensus. The implementation of ergonomic measures at the department is performed by the working group. To improve the implementation process, so-called 'ergocoaches' are trained. The primary outcome measure is an episode of LBP and NP. Secondary outcome measures are actual use of ergonomic measures, physical workload, psychosocial workload, intensity of pain, general health status, sick leave, and work productivity. The cost-effectiveness analysis is performed from the societal and company perspective. Outcome measures are assessed using questionnaires at baseline and after 6 and 12 months. Data on the primary outcome as well as on intensity of pain, sick leave, work productivity, and health care costs are collected every 3 months.
Discussion: Prevention of LBP and NP is beneficial for workers, employers, and society. If the intervention is proven (cost-)effective, the intervention can have a major impact on LBP and NP prevention and, thereby, on work disability prevention. Results are expected in 2010.
Trial Registration: ISRCTN27472278.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588446 | PMC |
http://dx.doi.org/10.1186/1471-2474-9-145 | DOI Listing |
Vaccines (Basel)
September 2024
Department of Health Sciences, University of Florence, 50134 Florence, Italy.
Haematologica
August 2024
Antonino Trizzino, Simona Gobbi, Fraia Melchionda, Marco Zecca, Elena Mastrodicasa, Massimo Provenzi, Monica Cellini, Daniela Onofrillo, Marco Rabusin, Bernd Raffeiner, Rosamaria Mura, Vito Miraglia, Alessandra Tozzo.
Primary hemophagocytic lymphohistiocytosis (pHLH) is a severe, life-threatening hyperinflammatory syndrome caused by defects in genes of the granule-dependent cytotoxic pathway. Here we investigated the clinical presentation and outcome in a large cohort of 143 patients with pHLH diagnosed in the last 15 years and enrolled in the Italian registry. The median age at diagnosis was 12 months (interquartile range, 2-81), and 92 patients (64%) fulfilled the HLH-2004 criteria.
View Article and Find Full Text PDFDiving Hyperb Med
December 2023
Prepared by the Working Group «SAFETY» of the COST Action B14 «HYPERBARIC OXYGEN THERAPY» May 2004 - Update 2022.
J Fungi (Basel)
September 2023
Kashkin Research Institute of Medical Mycology; North-Western State Medical University Named after I.I. Mechnikov, 191015 Saint-Petersburg, Russia.
We studied the risk factors, etiology, clinical manifestations, and treatment outcomes of COVID-19-associated invasive candidiasis (COVID-IC) in adult patients admitted to six medical facilities in St. Petersburg. (November 2020-December 2022).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!